Topics

Syntimmune, Inc. Company Profile

15:34 EDT 19th September 2019 | BioPortfolio

Founded in 2013, Syntimmune is advancing novel therapies based on its leading position in the biology of the neonatal Fc receptor (FcRn). FcRn is a well-validated target for IgG-mediated autoimmune diseases and represents a central common pathway that enables abnormal IgG responses. Syntimmune’s lead candidate, SYNT001, is a biologic progressing through IND-enabling studies that specifically blocks the FcRn-IgG interaction and is being developed for the treatment of IgG-mediated autoimmune diseases. Syntimmune has two additional, earlier-stage therapeutic programs, targeting other unique aspects of FcRn biology. The Syntimmune team has world-class experience in the field of FcRn biology and has successfully pioneered and advanced biologics targeting FcRn, including approved therapies currently on the market. Since its founding, the Company has received a total of $28 million in funding commitments from leading life sciences investors, including Apple Tree Partners, Baxalta Ventures, and Partners Innovation Fund. For more information on Syntimmune, please visit the Company’s website at www.syntimmune.com.


News Articles [1 Associated News Articles listed on BioPortfolio]

Cadent Therapeutics Appoints John McBride CFO

John McBride has been appointed chief financial officer of Cadent Therapeutics. He was most recently the CFO of Syntimmune, which was acquired by Alexion Pharmaceuticals (NASDAQ: ALXN) last year. Camb...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Syntimmune, Inc.

Founded in 2013, Syntimmune is advancing novel therapies based on its leading position in the biology of the neonatal Fc receptor (FcRn). FcRn is a well-validated target for IgG-m...

More Information about "Syntimmune, Inc." on BioPortfolio

We have published hundreds of Syntimmune, Inc. news stories on BioPortfolio along with dozens of Syntimmune, Inc. Clinical Trials and PubMed Articles about Syntimmune, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Syntimmune, Inc. Companies in our database. You can also find out about relevant Syntimmune, Inc. Drugs and Medications on this site too.

Quick Search

Relevant Topics

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...

Autoimmune Disorders
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...


Corporate Database Quicklinks



Searches Linking to this Company Record